Roche Taps New Pharma Head After Genentech Buy

Roche Holding AG named the architect of its integration plan with Genentech to head the Swiss group’s dominant drugs business, putting the finishing touches to this spring’s $47 billion buyout of the U.S. biotech firm.
Forbes